scholarly journals Mucosal HIV‐Binding Antibody and Neutralizing Activity in High‐Risk HIV‐Uninfected Female Participants in a Trial of HIV‐Vaccine Efficacy

2007 ◽  
Vol 196 (11) ◽  
pp. 1637-1644 ◽  
Author(s):  
John A. Schneider ◽  
Shaheen A. Alam ◽  
Marta Ackers ◽  
Bharat Parekh ◽  
Hua Yun Chen ◽  
...  
Keyword(s):  
High Risk ◽  
Vaccine Efficacy ◽  
Hiv Vaccine ◽  
Neutralizing Activity ◽  
Binding Antibody ◽  
Uninfected Female

scholarly journals Willingness to participate in HIV vaccine efficacy trials among high risk men and women from fishing communities along Lake Victoria in Uganda

Vaccine ◽  
2013 ◽  
Vol 31 (44) ◽  
pp. 5055-5061 ◽  
Author(s):  
Gershim Asiki ◽  
Andrew Abaasa ◽  
Eugene Ruzagira ◽  
Freddie Kibengo ◽  
Ubaldo Bahemuka ◽  
...  
Keyword(s):  
High Risk ◽  
Vaccine Efficacy ◽  
Lake Victoria ◽  
Hiv Vaccine ◽  
Fishing Communities ◽  
Willingness To Participate ◽  
Men And Women ◽  
Efficacy Trials

Pregnancies among high-risk women in the first ever HIV vaccine efficacy trial

AIDS ◽  
2003 ◽  
Vol 17 (5) ◽  
pp. 787-788 ◽  
Author(s):  
Pamela Brown-Peterside ◽  
Leigh Ren ◽  
Adrian Hirsch ◽  
Marc Drucker ◽  
Beryl A Koblin
Keyword(s):  
High Risk ◽  
Vaccine Efficacy ◽  
Hiv Vaccine ◽  
Efficacy Trial ◽  
High Risk Women ◽  
Hiv Vaccine Efficacy Trial

Identification of a High-Risk Heterosexual Cohort for HIV Vaccine Efficacy Trials in Rio de Janeiro, Brazil, Using a Sensitive/Less-Sensitive Assay: An Update

2004 ◽  
Vol 36 (3) ◽  
pp. 880-881 ◽  
Author(s):  
Paulo Feijó Barroso ◽  
Lee H. Harrison ◽  
Maria de Fátima Melo ◽  
Sônia Maria Batista ◽  
Marilene da Silva Bastos ◽  
...  
Keyword(s):  
High Risk ◽  
Vaccine Efficacy ◽  
Rio De Janeiro ◽  
Hiv Vaccine ◽  
Sensitive Assay ◽  
Efficacy Trials

scholarly journals Feasibility of Identifying a Cohort of US Women at High Risk for HIV Infection for HIV Vaccine Efficacy Trials

2013 ◽  
Vol 63 (2) ◽  
pp. 239-244 ◽  
Author(s):  
Beryl A. Koblin ◽  
Barbara Metch ◽  
Richard M. Novak ◽  
Cecilia Morgan ◽  
Debbie Lucy ◽  
...  
Keyword(s):  
High Risk ◽  
Hiv Infection ◽  
Vaccine Efficacy ◽  
Hiv Vaccine ◽  
Efficacy Trials

scholarly journals Feasibility of Identifying a Female Sex Worker Cohort at High Risk of HIV Infection in the Caribbean for HIV Vaccine Efficacy Trials

2016 ◽  
Vol 71 (1) ◽  
pp. 70-77 ◽  
Author(s):  
Marie M. Deschamps ◽  
Barbara Metch ◽  
Cecilia A. Morgan ◽  
Carmen D. Zorilla ◽  
Yeycy Donastorg ◽  
...  
Keyword(s):  
High Risk ◽  
Hiv Infection ◽  
Vaccine Efficacy ◽  
Hiv Vaccine ◽  
Female Sex Worker ◽  
Sex Worker ◽  
Female Sex ◽  
Efficacy Trials ◽  
The Caribbean

Readiness of high-risk populations in the HIV Network for Prevention Trials to participate in HIV vaccine efficacy trials in the United States

AIDS ◽  
1998 ◽  
Vol 12 (7) ◽  
pp. 785-793 ◽  
Author(s):  
Beryl A. Koblin ◽  
Patrick Heagerty ◽  
Amy Sheon ◽  
Susan Buchbinder ◽  
Connie Celum ◽  
...  
Keyword(s):  
United States ◽  
High Risk ◽  
Vaccine Efficacy ◽  
The United States ◽  
Hiv Vaccine ◽  
Efficacy Trials ◽  
High Risk Populations ◽  
Prevention Trials

scholarly journals Feasibility of recruiting high-risk women in the US for HIV vaccine efficacy trials (HVTN 906)

Retrovirology ◽  
2012 ◽  
Vol 9 (Suppl 2) ◽  
pp. P123
Author(s):  
B Koblin ◽  
B Metch ◽  
C Morgan ◽  
R Novak ◽  
E Swann ◽  
...  
Keyword(s):  
High Risk ◽  
Vaccine Efficacy ◽  
Hiv Vaccine ◽  
High Risk Women ◽  
Efficacy Trials ◽  
The Us

scholarly journals Neutralization of SARS-CoV-2 with IgG from COVID-19-convalescent plasma

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Kenji Maeda ◽  
Nobuyo Higashi-Kuwata ◽  
Noriko Kinoshita ◽  
Satoshi Kutsuna ◽  
Kiyoto Tsuchiya ◽  
...  
Keyword(s):  
Immune Response ◽  
Clinical Utility ◽  
Plasma Sample ◽  
Temporal Changes ◽  
Rapid Decline ◽  
Multiple Endpoints ◽  
Neutralization Activity ◽  
Neutralizing Activity ◽  
Binding Antibody ◽  
Potent Immune Response

AbstractWhile there are various attempts to administer COVID-19-convalescent plasmas to SARS-CoV-2-infected patients, neither appropriate approach nor clinical utility has been established. We examined the presence and temporal changes of the neutralizing activity of IgG fractions from 43 COVID-19-convalescent plasmas using cell-based assays with multiple endpoints. IgG fractions from 27 cases (62.8%) had significant neutralizing activity and moderately to potently inhibited SARS-CoV-2 infection in cell-based assays; however, no detectable neutralizing activity was found in 16 cases (37.2%). Approximately half of the patients (~ 41%), who had significant neutralizing activity, lost the neutralization activity within ~ 1 month. Despite the rapid decline of neutralizing activity in plasmas, good amounts of SARS-CoV-2-S1-binding antibodies were persistently seen. The longer exposure of COVID-19 patients to greater amounts of SARS-CoV-2 elicits potent immune response to SARS-CoV-2, producing greater neutralization activity and SARS-CoV-2-S1-binding antibody amounts. The dilution of highly-neutralizing plasmas with poorly-neutralizing plasmas relatively readily reduced neutralizing activity. The presence of good amounts of SARS-CoV-2-S1-binding antibodies does not serve as a surrogate ensuring the presence of good neutralizing activity. In selecting good COVID-19-convalescent plasmas, quantification of neutralizing activity in each plasma sample before collection and use is required.

scholarly journals Contrasting Adult and Infant Immune Responses to HIV Infection and Vaccination

2015 ◽  
Vol 23 (2) ◽  
pp. 84-94 ◽  
Author(s):  
David R. Martinez ◽  
Sallie R. Permar ◽  
Genevieve G. Fouda
Keyword(s):  
Immune Responses ◽  
Hiv Infection ◽  
Vaccine Efficacy ◽  
Neutralizing Antibody ◽  
Hiv Vaccine ◽  
Antibody Responses ◽  
Hiv Vaccines ◽  
Vaccine Candidates ◽  
Protective Antibodies ◽  
Pediatric Populations

ABSTRACTExtensive studies have demonstrated that infant immune responses are distinct from those of adults. Despite these differences, infant immunization can elicit protective immune responses at levels comparable to or, in some cases, higher than adult immune responses to many vaccines. To date, only a few HIV vaccine candidates have been tested in infant populations, and none of them evaluated vaccine efficacy. Recent exciting studies showing that HIV-infected infants can develop broad neutralizing antibody responses and that some HIV vaccine regimens can elicit high levels of potentially protective antibodies in infants provide support for the development and testing of HIV vaccines in pediatric populations. In this review, we discuss the differences in adult and infant immune responses in the setting of HIV infection and vaccination.

Sign in / Sign up

Export Citation Format

Share Document